ATOS
ATOSSA THERAPEUTICS, INC.
NASDAQ · Healthcare · Biotechnology · US
$2.56
−12.03%Oct 9, 2026, 12:00 UTC
Atossa Therapeutics declared a dividend of one stapled contingent value right for each common share outstanding on October 19, 2026, or issued thereafter, entitling holders to 25% of net proceeds from monetization of its first qualifying priority review voucher, subject to a $50 million aggregate cap.
Source:Jun 11, 2026, 00:00 UTC
Atossa Therapeutics entered into a securities purchase agreement for a registered direct offering of 1,363,638 shares of common stock and accompanying warrants, with expected net proceeds of approximately $4.1 million.
Source: